Open AccessClinical significance and novel mechanism of action of kallikrein 6 in glioblastoma
Author(s) -
Kristen Drucker,
Alex R. Paulsen,
Caterina Giannini,
Paul A. Decker,
Sachiko I. Blaber,
Michael Blaber,
Joon H. Uhm,
Brian Patrick O’Neill,
Robert B. Jenkins,
Isobel A. Scarisbrick
Publication year - 2013
Publication title -
neuro-oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 4.005
H-Index - 125
eISSN - 1523-5866
pISSN - 1522-8517
DOI - 10.1093/neuonc/nos313
Subject(s) - temozolomide , cancer research , cytotoxic t cell , medicine , oncology , astrocytoma , glioblastoma , pathology , chemistry , in vitro , biochemistry
Kallikreins have prognostic value in specific malignancies, but few studies have addressed their clinical significance to glioblastoma multiforme (GBM). Kallikrein 6 (KLK6) is of potential high relevance to GBM, since it is upregulated at sites of CNS pathology and linked to reactive astrogliosis. Here we examine the clinical value of KLK6 as a prognostic indicator of GBM patient survival and its activity in promoting resistance to cytotoxic agents.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom